LDLR and neoplasm: Next, we targeted HER2, which is frequently upregulatedin cancerand linked to breast cancer invasiveness and tumor progression. We generated an HER2-targeting LIPTAC by incorporatinganti-HER2 trastuzumab (Traz) scFv with our LDLR Fab.